Rona Therapeutics Launches First Bi-valent siRNA for Heart Disease Risk Reduction Rona Therapeutics has submitted RN5681 for clinical development, marking a revolutionary advancement in RNAi medicine aimed at reducing cardiovascular risk factors.

Rona Therapeutics Launches First Bi-valent siRNA for Heart Disease Risk Reduction #Australia #Santa_Barbara #Rona_Therapeutics #siRNA #RN5681

Rona Therapeutics Launches Innovative Bi-valent siRNA for Cardiovascular Risk Management Rona Therapeutics has taken a significant step forward in cardiovascular health with its bi-valent siRNA RN5681, aiming to enhance treatment outcomes for patients.

Rona Therapeutics Launches Innovative Bi-valent siRNA for Cardiovascular Risk Management #None #Rona_Therapeutics #RN5681 #bi-valent_siRNA